863034-65-5

Upstream product

• 863034-64-4 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 861151-12-4 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydro-1H-pyrazole-3-carboxamide 
• 920526-48-3 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid hydrazide 

Relevant academic research and scientific papers

Substituted pyrazoline for preventing weight gain

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

Active substance combination for the treatment of diabetes

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation

Combination of substituted pyrazolines and agent for treating dyslipidemia

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one lipid lowering compound used to treat dyslipidaemia, a medicament comprising said active substance combination, a pha

A-polymorph of a substituted pyrazoline, its preparation and use as medicaments

The present invention relates to the α-Polymorph of (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide, methods for its preparation, medicaments comprising this compound as well as their use for the prepara

Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators

The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

Combination of a substituted pyrazoline compound and a drug used in food-related disorders

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one compound used in food-related disorders, a medicament comprising said active substance combination, a pharmaceutical

Use of substituted pyrazoline compounds for the preparation of paediatric medicaments

The present invention relates to the use of substituted pyrazoline compounds for the manufacture of a medicament for prophylaxis and/or treatment of a food-related disorder in a paediatric patient, whereby said medicament is administered at a dosage of 0.

Combination of pyrazoline type cannabinoid receptor antagonist and statin

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one statin compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising s

Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome

The present invention relates to the use of substituted pyrazoline compounds for the manufacture of a medicament for the treatment of metabolic syndrome.

Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes

The present invention relates to the use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes.